← Back to home

FDA Approves Genentech's Enspryng for Thyroid Eye Disease as an Injection Patients Can Give at Home

Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources

Brief

Genentech said on Oct. 15, 2026, that the U.S. Food and Drug Administration had approved Enspryng (satralizumab-mwge) for adults with thyroid eye disease, an autoimmune…

Keep reading with NewsPlain Premium

Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.

4 sources behind this story.

About this story

We haven’t published a correction to this story.

How NewsPlain works
← Back to home